<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512902</url>
  </required_header>
  <id_info>
    <org_study_id>CST1571EUS210</org_study_id>
    <nct_id>NCT00512902</nct_id>
  </id_info>
  <brief_title>A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis</brief_title>
  <official_title>Pilot Study to Examine The Use of Imatinib (Gleevec) For The Treatment of Active Alveolitis in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of imatinib (gleevec) in
      subjects who have systemic sclerosis. Imatinib has been approved by the FDA for the treatment
      of newly diagnosed adult patients with CML (newly diagnosed adult patients and for the
      treatment of patients with an accelerated phase. Imatinib is also approved for the treatment
      of patients with a certain type of gastrointestinal cancer (called stromal tumors) but it has
      not been approved to treat systemic sclerosis. Imatinib works by interfering with an enzyme
      called tyrosine phosphatase resulting in suppression of the immune system. It als interferes
      with a protein called platelet derived growth factor receptor (PDGFr) that has been linked to
      increased fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis is a rare, progressive disease that leads to hardening and tightening of
      the skin and connective tissues. It usually begins with a few dry patches of skin on the
      hands or face that begin getting thicker and harder. These patches then spread to other areas
      of the skin. In some cases, systemic sclerosis also affects the blood vessels an internal
      organs. Systemic sclerosis is one of a group of arthritic conditions called connective tissue
      disorders, a person's antibodies are directed against their own tissues.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Adverse Events</measure>
    <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
    <description>Treatment-related adverse events requiring discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FVC (Forced Vital Capacity)</measure>
    <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
    <description>Measures the amount of air breathed out as a percent of predicted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TLC (Total Lung Capacity)</measure>
    <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
    <description>No measures of dispersion was available for TLC as data were lost. This describes the total lung capacity as a percent of predicted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLco</measure>
    <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
    <description>DLCO (diffusing capacity or transfer factor of the lung for carbon monoxide (CO)) is the extent to which oxygen passes from the air sacs of the lungs into the blood. Commonly, it refers to the test used to determine this parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Rodnan Skin Score (MRSS)</measure>
    <time_frame>Baseline vs. Endpoint</time_frame>
    <description>No measures of dispersion was available as data were lost. The range of this measure is 0 to 51 and measures the extent of skin thickening with higher numbers representing thickening.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alveolitis</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Up to 600 mg QD PO for up to 1 year.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must fulfill the criteria for SSc by ACR criteria

          2. Age of entry into the study ≥ 18 yrs

          3. FVC &lt;85% of predicted.

          4. Able to complete the 6MWT with a walking distance ≥ 150 m

          5. Patients must have dyspnea on exertion (grade ≥ 2 on the Magnitude of Task component
             of the Mahler Modified Dyspnea Index).

          6. SSc for ≤ 10 years, with onset defined as the date of the first non-Raynaud
             manifestation typical of systemic sclerosis.

          7. Patients may have limited (cutaneous thickening distal but not proximal to elbows and
             knees, with or without facial involvement) or diffuse (cutaneous thickening proximal
             to elbows and knees, often involving the chest or abdomen) cutaneous SSc (Medsger
             1995).

          8. Patients must show some evidence of alveolitis as defined by an HRCT of the lung which
             shows ground glass opacification as a radiographic marker of &quot;alveolitis&quot; or finely
             reticulated fibrosis or they must have alveolitis by BAL ( ≥ 3% PMN's or ≥ 2%
             eosinophils).

          9. Female patients of childbearing potential must have negative pregnancy test within 7
             days before initiation of study drug dosing.

         10. Patients must be able to provide written voluntary informed consent.

        Exclusion Criteria:

          1. FVC ≤ 50% of predicted or DLCO (corrected for Hgb but not for alveolar volume) ≤ 35%
             of predicted (suggesting severe probably irreparable disease and/or significant
             pulmonary vascular involvement by SSc).

          2. FEV1/FVC ratio &lt;65% (to exclude significant airflow obstruction)

          3. Clinically significant abnormalities on HRCT not attributable to SSc (e.g., lung mass,
             extensive scarring due to previous infection, etc.)

          4. Clinically significant pulmonary hypertension documented on right heart
             catheterization (i.e., right ventricular systolic pressure of &gt;50 mm Hg and/or mean
             PAP ≥30 mm Hg) pulmonary pressure or echocardiographic evidence of PAH (if echo
             cardiographic systolic pressure ≥ 55 mmHg) or FVC/DLCO ratio &gt;1.6 on pulmonary
             function testing

          5. Persistent unexplained hematuria (&gt;10 RBCs/hpf).

          6. History of persistent leukopenia (white blood cell count &lt;3500), neutropenia (absolute
             neutrophil count &lt; 1500) or thrombocytopenia (platelet count &lt;100,000).

          7. Clinically significant anemia (&lt;9.0 gm/dl)

          8. Serum creatinine &gt;ULN.

          9. Pregnancy (documented by urine pregnancy test), breast feeding

         10. If of child-bearing potential, failure regularly to employ a reliable means of
             contraception

         11. Active infection of the lung or elsewhere, whose management would be compromised by
             Imatinib

         12. Unreliability, drug abuse (including active alcoholism)

         13. Any chronic, debilitating illness (other than SSc)

         14. Smoking of cigars, pipes or cigarettes during the past 6 months

         15. Baseline liver function tests (ALT or AST or bilirubin &gt;1.5 x upper limit of normal

         16. Previous use of prednisone &gt; 10 mg per day. If on prednisone ≤10 mg/d, dose must have
             been stable for &gt; 1 month.

         17. All other medication with putative disease-modifying properties (e.g.,
             D-penicillamine, cyclophosphamide, azathioprine, methotrexate, colchicine, Potaba)
             must be discontinued 1 month prior to beginning study medication.

         18. Patient is &lt; 5 years since she/he had a primary malignancy except: if the other
             primary malignancy is not currently clinically significant nor requiring active
             intervention, or if other primary malignancy is a basal cell skin cancer or a cervical
             carcinoma in situ. Existence of any other malignant disease is not allowed except
             after consultation with the PI.

         19. Patient with Grade III/IV cardiac problems as defined by the New York Heart
             Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6
             months of study)

         20. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,
             chronic renal disease, or active uncontrolled infection).

         21. Patient has known chronic liver disease (i.e., chronic active hepatitis and
             cirrhosis).

         22. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

         23. Use of contraindicated medications at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel E. Furst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011 Nov;63(11):3540-6. doi: 10.1002/art.30548.</citation>
    <PMID>21769849</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>April 20, 2012</results_first_submitted>
  <results_first_submitted_qc>October 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2014</results_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Daniel Furst</investigator_full_name>
    <investigator_title>M.D., Carl M Pearson Professor of Rheumatology</investigator_title>
  </responsible_party>
  <keyword>active alveolitis in systemic sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>University setting convenience samples.</recruitment_details>
      <pre_assignment_details>1-year, Phase I/IIa, Open-label trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Imatinib</title>
          <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imatinib</title>
          <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.1" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Adverse Events</title>
        <description>Treatment-related adverse events requiring discontinuation.</description>
        <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib</title>
            <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Adverse Events</title>
          <description>Treatment-related adverse events requiring discontinuation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FVC (Forced Vital Capacity)</title>
        <description>Measures the amount of air breathed out as a percent of predicted.</description>
        <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib</title>
            <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FVC (Forced Vital Capacity)</title>
          <description>Measures the amount of air breathed out as a percent of predicted.</description>
          <units>Percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TLC (Total Lung Capacity)</title>
        <description>No measures of dispersion was available for TLC as data were lost. This describes the total lung capacity as a percent of predicted.</description>
        <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib</title>
            <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TLC (Total Lung Capacity)</title>
          <description>No measures of dispersion was available for TLC as data were lost. This describes the total lung capacity as a percent of predicted.</description>
          <units>Percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17">Data was lost.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DLco</title>
        <description>DLCO (diffusing capacity or transfer factor of the lung for carbon monoxide (CO)) is the extent to which oxygen passes from the air sacs of the lungs into the blood. Commonly, it refers to the test used to determine this parameter.</description>
        <time_frame>Baseline vs. Endpoint (1 year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib</title>
            <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DLco</title>
          <description>DLCO (diffusing capacity or transfer factor of the lung for carbon monoxide (CO)) is the extent to which oxygen passes from the air sacs of the lungs into the blood. Commonly, it refers to the test used to determine this parameter.</description>
          <units>Percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46">Data was lost.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Rodnan Skin Score (MRSS)</title>
        <description>No measures of dispersion was available as data were lost. The range of this measure is 0 to 51 and measures the extent of skin thickening with higher numbers representing thickening.</description>
        <time_frame>Baseline vs. Endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib</title>
            <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Rodnan Skin Score (MRSS)</title>
          <description>No measures of dispersion was available as data were lost. The range of this measure is 0 to 51 and measures the extent of skin thickening with higher numbers representing thickening.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9">Data was lost.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Imatinib</title>
          <description>Systemic Sclerosis patients administered oral 600 mg imatinib once per day for up to one year.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated CPK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Facial/lower extremity edema</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mild hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label, small.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Furst, Carl M Pearson Professor of Rheumatology</name_or_title>
      <organization>University of California at Los Angeles</organization>
      <phone>310-794-9504</phone>
      <email>defurst@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

